Pesquisar
Theratechnologies Inc
THTXAdicionar à lista de desejos
3.390USD
0.0000.00%
Fechamento 07/02, 13:00（ET）Cotações atrasadas em 15 min
155.87MValor de mercado
PerdaP/L TTM
Mais detalhes de Theratechnologies Inc Empresa
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.
Informações de Theratechnologies Inc
Código da empresaTHTX
Nome da EmpresaTheratechnologies Inc
Data de listagemDec 21, 1993
CEOMr. Paul Levesque
Número de funcionários94
Tipo de títulosOrdinary Share
Fim do ano fiscalDec 21
Endereço2015 Peel Street, 11th Floor
CidadeMONTREAL
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísCanada
Código postalH3A 1T8
Telefone15143367800
Sitehttps://www.theratech.com/
Código da empresaTHTX
Data de listagemDec 21, 1993
CEOMr. Paul Levesque
Executivos da empresa Theratechnologies Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Jocelyn Lafond
Mr. Jocelyn Lafond
General Counsel, Company Secretary
General Counsel, Company Secretary
--
-100.00%
Mr. Joseph P. Arena
Mr. Joseph P. Arena
Independent Director
Independent Director
--
--
Mr. John Leasure
Mr. John Leasure
Global Commercial Officer
Global Commercial Officer
--
-100.00%
Mr. Paul Levesque
Mr. Paul Levesque
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
-100.00%
Mr. Frank A. Holler
Mr. Frank A. Holler
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
-100.00%
Dr. Christian Marsolais, Ph.D.
Dr. Christian Marsolais, Ph.D.
Senior Vice President, Chief Medical Officer
Senior Vice President, Chief Medical Officer
--
-100.00%
Ms. Dale Maccandlish Weil
Ms. Dale Maccandlish Weil
Independent Director
Independent Director
--
-100.00%
Mr. Andre Dupras
Mr. Andre Dupras
Vice President of Human Resources
Vice President of Human Resources
--
--
Ms. Elina Tea
Ms. Elina Tea
Independent Director
Independent Director
--
--
Mr. Andrew Thomas Molson
Mr. Andrew Thomas Molson
Independent Director
Independent Director
--
-100.00%
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Jocelyn Lafond
Mr. Jocelyn Lafond
General Counsel, Company Secretary
General Counsel, Company Secretary
--
-100.00%
Mr. Joseph P. Arena
Mr. Joseph P. Arena
Independent Director
Independent Director
--
--
Mr. John Leasure
Mr. John Leasure
Global Commercial Officer
Global Commercial Officer
--
-100.00%
Mr. Paul Levesque
Mr. Paul Levesque
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
-100.00%
Mr. Frank A. Holler
Mr. Frank A. Holler
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
-100.00%
Dr. Christian Marsolais, Ph.D.
Dr. Christian Marsolais, Ph.D.
Senior Vice President, Chief Medical Officer
Senior Vice President, Chief Medical Officer
--
-100.00%
Perguntas frequentes
Quem são os cinco principais acionistas de Theratechnologies Inc?
Os cinco principais acionistas de Theratechnologies Inc são: Mr. Jocelyn Lafond
Quantas instituições possuem ações da Theratechnologies Inc (THTX)?
Em 2026Q1, 78 instituições possuíam ações da Theratechnologies Inc, com valor de mercado aproximado de 293.53K, representando 0.64% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -22862543.00.
Qual é a maior fonte de receita da Theratechnologies Inc?
Em 2026Q1, o segmento de negócios EGRIFTA gerou a maior receita para Theratechnologies Inc, totalizando 11.13M e representando 62.78% da receita total.